VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune
system and stop cancer cells from growing.
PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have
advanced or metastatic solid tumors that have not responded to previous therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Vion Pharmaceuticals
Treatments:
Cefixime Ceftriaxone Ciprofloxacin Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination